Wong Jillian W, Koo John Y M
University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.
Background. Patients with moderate-to-severe psoriasis are often treated with systemic immunosuppressant agents that decrease immune system function. For the elderly, these medications are often problematic due to their already immunosuppressed state and comorbidities. However, there are few studies examining the effects of these medications on the elderly age group. Therefore, there is often discomfort among dermatologists treating elderly patients with psoriasis in utilizing systemic agents, frequently resulting in inadequate treatment. Objective. We review the safety profiles of systemic treatments often used to treat psoriasis and their possible adverse risks to the geriatric population. Methods. We conducted a search of PubMed's Medline database of articles published from 2000 to 2011, which resulted in 14 articles. Conclusion. Treating geriatric patients with moderate-to-severe psoriasis remains a challenge due to immunosenescence and comorbidities. More studies focusing on psoriasis treatment safety in the geriatric population are needed.
背景。中重度银屑病患者常接受可降低免疫系统功能的全身性免疫抑制剂治疗。对于老年人而言，由于他们本身处于免疫抑制状态且存在合并症，这些药物往往存在问题。然而，很少有研究考察这些药物对老年人群的影响。因此，皮肤科医生在使用全身性药物治疗老年银屑病患者时常常感到不适，这常常导致治疗不充分。目的。我们回顾常用于治疗银屑病的全身性治疗方法的安全性概况及其对老年人群可能产生的不良风险。方法。我们检索了2000年至2011年发表在PubMed的Medline数据库中的文章，共检索到14篇文章。结论。由于免疫衰老和合并症，治疗老年中重度银屑病患者仍然是一项挑战。需要更多关注老年人群银屑病治疗安全性的研究。
